Clopidogrel Resistance is Associated with Long-Term Thrombotic Events in Patients Implanted with Drug-Eluting Stents
Background: There are limited prospective data on clopidogrel resistance and clinical outcome of patients with selective coronary drug-eluting stent (DES) implantation.
Objective: To investigate whether clopidogrel resistance is associated with longterm thrombotic events in patients with selective coronary DES implantation.
Methods: A total of 154 patients who underwent selective percutaneous coronary intervention (PCI) with DES were enrolled in this study. Platelet aggregation was measured using light transmittance aggregometry (LTA) before clopidogrel administration (baseline) and 24 hours after loading with clopidogrel 300 mg. Clopidogrel resistance was defined as ≤10% absolute difference between baseline aggregation and post-administration aggregation. All patients who received the same anti-platelet treatment were followed up for 1 year after discharge for the incidence of a composite endpoint consisting of cardiovascular death, myocardial infarction (MI) and revascularization, and secondly for the incidence of stent thrombosis.
Results: The incidence of clopidogrel resistance is 20.28% in our study population. Patients who are complicated by diabetes mellitus, smoke, or have a higher body mass index (BMI) tend to have clopidogrel resistance. Patients in the clopidogrel-resistant group have significantly higher incidences of composite endpoints (21.88% vs 4.92%; p = 0.006) and stent thrombosis (12.5% vs 1.64%; p= 0.017) than patients in the clopidogrel-response group during 1-year follow-up.
Conclusions: Diabetes, smoking, and high BMI are associated with clopidogrel resistance, and clopidogrel resistance indicates an increased risk of long-term thrombotic events in patients implanted with DES.
- American College of Cardiology, American Heart Association Task Force on Practice Guidelines. 2007 focused update of the ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Catheter Cardiovasc Interv 2008; 71: E1–40
- Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Variability in individual responsiveness to clopidogrel: clinical implications, management, and future perspectives. J Am Coll Cardiol 2007; 49: 1505–16 CrossRef
- Eikelboom JW, Hirsh J, Weitz JI, et al. Aspirin-resistant thromboxane biosynthesis and the risk of myocardial infarction, stroke, or cardiovascular death in patients at high risk for cardiovascular events. Circulation 2002; 105: 1650–5 CrossRef
- Matetzky S, Shenkman B, Guetta V, et al. Clopidogrel resistance is associated with increased risk of recurrent atherothrombotic events in patients with acute myocardial infarction. Circulation 2004; 109: 3171–5 CrossRef
- Gurbel PA, Bliden KP, Samara W, et al. Clopidogrel effect on platelet reactivity in patients with stent thrombosis: results of the CREST Study. J Am Coll Cardiol 2005; 46: 1827–32 CrossRef
- Barragan P, Bouvier JL, Roquebert PO, et al. Resistance to thienopyridines: clinical detection of coronary stent thrombosis by monitoring of vasodilator-stimulated phosphoprotein phosphorylation. Catheter Cardiovasc Interv 2003; 59: 295–302 CrossRef
- Gurbel PA, Bliden KP, Hiatt BL, et al. Clopidogrel for coronary stenting: response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107 (23): 2908 CrossRef
- Cannon CP, Battler A, Brindis RG, et al. American College of Cardiology key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes: a report of the American College of Cardiology Task Force on Clinical Data Standards (Acute Coronary Syndromes Writing Committee). J Am Coll Cardiol 2001; 38: 2114–30 CrossRef
- Angiolillo DJ, Suryadevara S, Capranzano P, et al. Antiplatelet drug response variability and the role of platelet function testing: a practical guide for interventional cardiologists. Catheter Cardiovasc Interv 2009; 73 (1): 1–14 CrossRef
- Wang TH, Bhatt DL, Topol EJ. Aspirin and clopidogrel resistance: an emerging clinical entity. Eur Heart J 2006; 27: 647–54 CrossRef
- Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, et al. Platelet function profiles in patients with type 2 diabetes and coronary artery disease on combined aspirin and clopidogrel treatment. Diabetes 2005; 54: 2430–5 CrossRef
- Ferroni P, Basili S, Falco A, et al. Platelet activation in type 2 diabetes mellitus. J Thromb Haemost 2004; 2: 1282–91 CrossRef
- Lau WC, Gurbel PA, Watkins PB, et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidogrel resistance. Circulation 2004; 109: 166–71 CrossRef
- Zevin S, Benowitz NL. Drug interactions with tobacco smoking. Clin Pharmacokinet 1999; 36: 425–38 CrossRef
- Iba MM, Fung J, Pak YW, et al. Dose-dependent up-regulation of rat pulmonary, renal, and hepatic cytochrome P-450 (CYP) 1A expression by nicotine feeding. DrugMetab Dispos 1999; 27: 977–82
- Angiolillo DJ, Fernández-Ortiz A, Bernardo E, et al. Platelet aggregation according to body mass index in patients undergoing coronary stenting: should clopidogrel loading-dose be weight adjusted? J Invasive Cardiol 2004; 16: 169–74
- Scherrer U, Nussberger J, Torriani S, et al. Effect of weight reduction in moderately overweight patients on recorded ambulatory blood pressure and free cytostolic platelet calcium. Circulation 1991; 83: 552–8 CrossRef
- Kotlyar M, Carson SW. Effects of obesity on the cytochrome P450 enzyme system. Int J Pharmacol Ther 1999; 37: 8–19
- Feher G, Koltai K, Alkonyi B, et al. Clopidogrel resistance: role of body mass and concomitant medications. Int J Cardiol 2007; 120 (2): 188–92 CrossRef
- Simon T, Verstuyft C, Pharm D. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360 (4): 363–75 CrossRef
- Mega JL, Close SL, Wiviott SD, et al. Cytochrome P2450 polymorphisms and response to clopidogrel. N Engl J Med 2009; 360 (4): 354–62 CrossRef
- Simon T, Verstuyft C, Mary-Krause M. Genetic determinants of response to clopidogrel and cardiovascular events. N Engl J Med 2009; 360 (4): 363–75 CrossRef
- Geisler T, Schaeffeler E, Dippon J. CYP2C19 and nongenetic factors predict poor responsiveness to clopidogrel loading dose after coronary stent implantation. Pharmacogenomics 2008; 9 (9): 1251–9 CrossRef
- Gao RL, Xu B, Chen JL, et al. Immediate and long-term outcomes of drug-eluting stent implantation for unprotected left main coronary artery disease: comparison with baremetal stent implantation. Am Heart J 2008; 155 (3): 553–61 CrossRef
- Migliorini A, Valenti R, Marcucci R, et al. High residual platelet reactivity after clopidogrel loading and long-term clinical outcome after drug-eluting stenting for unprotected left main coronary disease. Circulation 2009; 120 (22): 2214–21 CrossRef
- Lev EI, Patel RT, Maresh KJ, et al. Aspirin and clopidogrel drug response in patients undergoing percutaneous coronary intervention: the role of dual drug resistance. J Am Coll Cardiol 2006; 47 (1): 27–33 CrossRef
- Clopidogrel Resistance is Associated with Long-Term Thrombotic Events in Patients Implanted with Drug-Eluting Stents
- Open Access
- Available under Open Access This content is freely available online to anyone, anywhere at any time.
Drugs in R & D
Volume 10, Issue 4 , pp 219-224
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors